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Background: Prostate cancer is the most common male cancer in developed countries, and in Australia
approximately one-fifth of men with prostate cancer have advanced disease. By comparison to men with localised
prostate cancer, men with advanced disease report higher levels of psychological distress; poorer quality of life; and
have an increased risk of suicide. To date no psychological intervention research specifically targeting men with
advanced prostate cancer has been reported. In this paper we present the protocol of a current randomised
controlled trial to assess the effectiveness of a professionally-led mindfulness-based cognitive therapy (MBCT) group
intervention to improve psychological well-being in men with advanced prostate cancer.
Methods/design: Ninety-five men per condition (190 men in total) will be recruited through clinicians in the
Australian and New Zealand Urogenital and Prostate Cancer Trials Group and in major treatment centres in
Queensland, New South Wales, Victoria and Western Australia. Patients are randomised to: (1) tele-based MBCT
intervention or (2) patient education. A series of previously validated and reliable self-report measures will be
administered to men at four time points: baseline/recruitment, and at 3, 6, and 9 months after recruitment and
intervention commencement. Engagement with the principles of mindfulness and adherence to practice will be
included as potential mediators of intervention effect. Primary outcomes are anxiety, depression and cancer-specific
distress. Secondary outcomes are health-related quality of life (QoL) and benefit finding. Disease variables
(e.g. cancer grade, stage) will be assessed through medical records.
Discussion: This study will address a critical but as yet unanswered research question: to identify an effective way
to reduce psychological distress; and improve the quality of life for men with advanced prostate cancer.
Trial registration: ACTRN12612000306819
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Prostate cancer is the most common male cancer in
developed countries (excluding non-melanoma skin cancer).
In 2007, 19,403 Australian men were diagnosed with
prostate cancer [1]. Approximately 10-15% of men with
prostate cancer have locally advanced or metastatic pros-
tate cancer at diagnosis [2] and a further 20-40% of men* Correspondence: suzanne.chambers@griffith.edu.au
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reproduction in any medium, provided the orwith localised cancer at diagnosis experience recurrence
or progression after treatment [3]. Men with advanced
prostate cancer face additional physical and psychological
challenges compared to men with localised disease.
The iatrogenic effects of hormonal ablation, the main
treatment for advanced disease, include mood disturbance,
cognitive impairment, fatigue, and sexual dysfunction [4].
By comparison to men with localised prostate cancer, men
with advanced disease report higher levels of psychological
distress and poorer quality of life (QoL) [5,6]; and have
an increased risk of suicide [7,8]. Hence research intotral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adjustment is crucial for these men.
To date, no psychological intervention research spe-
cifically targeting men with advanced prostate cancer
has been reported [9]. In this study we propose using
the cognitive behavioural approach of Mindfulness-
Based Cognitive Therapy (MBCT) as relevant to this
patient group. Mindfulness involves open awareness of
current experience and the intention to observe habits
of reacting to difficulties as they arise. Over time, this
practice leads the person to gain the ability to be less
reactive to difficult experiences and approach equanimity
regarding the content of the illness experience, including
negative emotions and thoughts. MBCT specifically targets
the cognitive processes associated with depression by
encouraging participants to disengage from reactive and
ruminative states of mind, such as those that are commonly
reported by cancer patients [10,11]. Qualitative studies of
cancer patients who have taken part in mindfulness courses
have identified positive changes in acceptance, self-control,
personal growth, shared experience and self-regulation
as outcomes of mindfulness practice [12,13]. In a pilot
study of group MBCT conducted with 19 men with
advanced prostate cancer, men reported significant
changes in both general psychological and cancer-
specific distress [14]. Qualitative data revealed that
acceptance of and learning from other group members
were key aspects of the group context that contributed
to acceptance of progressive disease. Thus, in the
context of MBCT the group setting appears important as
a contributor to acceptance of cancer through peer
learning and modelling.
Accordingly, in this trial we apply a tele-based MBCT
group intervention to decrease anxiety and depression
and cancer-specific distress in men with advanced
prostate cancer.
Methods/design
The study has two arms: 1) MBCT delivered by tele-
conference over eight weekly sessions and (2) patient
education.
It is hypothesised that 3, 6 and 9 months after recruit-
ment and commencement of the intervention:
1. Relative to men who receive patient education, men
who receive MBCT will have lower anxiety and
depression.
2. Relative to men who receive patient education, men
who receive MBCT will have lower cancer-specific
distress.
3. Relative to men who receive patient education, men
who receive MBCT will have higher mindfulness.
4. Intervention-driven improvements in psychological
outcomes will be mediated by mindfulness skills.Group condition
Patient Education
Patient education consists of the man’s standard medical
management and a package containing existing evidence-
based patient education materials.
Mindfulness-Based Cognitive Therapy
The Mindfulness-Based Cognitive Therapy group inter-
vention (MBCT) follows a cancer-specific manual based
on Segal, Williams and Teasdale’s [15] manual for
MBCT, with novel specific components developed for
men with advanced prostate cancer in our pilot study
[14]. The sessions are facilitated by health professionals
with experience in oncology and professional training in
MBCT. The program has been further developed to be
suitable for telephone delivery. For example, facilitators
have been trained to use explicit communication such as
encouraging group members to say their name before
contributing, listen closely to the tone of participants'
voices, give extra time for responses, and have explicit
rules for how the group will interact. Each session runs
for 1.25-h and only short (up to 15 min) meditations are
provided during the group phone sessions to support
group engagement and alleviate practical concerns such
as holding the telephone receiver. As well, the material
in participant workbooks has been elaborated to provide
session plans, so participants can navigate phone
sessions more easily, and interactive worksheets are
provided to help keep group discussions on task. The
program includes eight weekly group teleconferences,
and each participant has an individual introductory call
with their facilitator to allow them to connect with the
facilitator, prepare them for the program and to enhance
motivation. Participants are provided with a handbook
summarising each weekly session; self-help materials
including Jon Kabat Zinn’s Full Catastrophe Living [16];
and an audio recorded meditation on compact disc.
Daily home practice of mindfulness meditation is
strongly encouraged; with participants asked to engage
in one of the four 35 min practices depending on the
stage of the course (the body scan, moving meditation,
mixed mindfulness meditation, silent practice with bells
at 5 min intervals). Finally, as in our pilot study, peer
interaction is directed towards support for the learning
of mindfulness skills and mutual support in facing the
challenges of advanced prostate cancer.
Participants
Recruitment is being undertaken through clinicians in
the Australian and New Zealand Urogenital and Prostate
Cancer Trials Group and in major treatment centres in
Queensland, New South Wales, Victoria and Western
Australia. Other recruitment avenues include the distri-
bution of information through prostate cancer support
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contact potential participants after referral to the study
obtains informed written consent. Figure 1 illustrates the
recruitment, intervention and data collection process.
Inclusion criteria are that the men must: (1) have proven
metastatic disease or castration resistant biochemical
progression; (2) be able to read and speak English; (3) have
no previous history of head injury, dementia or psychiatric
illness; (4) have no other concurrent cancer; (5) have
phone access.
Approximately 190 men will be recruited to the study
(allowing 30% attrition from treatment; 65 men in each
condition will complete final assessments). This sample
size would comfortably exceed 80% power to detect a
moderate to large effect over four assessment points.
Study integrity
Ethical approval has been obtained from the Griffith
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Figure 1 Flowchart of recruitment, intervention and assessment.PSY/15/12/HREC) and Metro-North – The Prince
Charles Hospital Human Research Ethics Committee
(HREC/12/QPCH/101). The study design is guided by the
CONSORT criteria [17]. Randomisation to study condition
occurs following the completion of baseline assessment.
Assessments are by self-report pen and paper measures
and project staff tracking assessments are blinded to condi-
tion where possible. Randomisation occurs in blocks of 14,
with each condition randomly generated 7 times within
each block to ensure an unpredictable allocation sequence
with equal numbers of men in each condition at the
completion of each block; and sufficient men to form a
tele-based group (of 7) in the MBCT condition. Random-
isation occurs within Queensland-Western Australia and
New South Wales-Victoria dyads to coincide with a two-
stage commencement of recruitment. The randomisation
sequence is undertaken by the project manager and
concealed from investigators. The group sessions are
audiotaped with 15% reviewed to ensure adherence to anReceive currently 
available and project-
specific printed 
information and resources. 
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of intention to treat.
Measures
A series of previously validated and reliable self-report
measures are administered by mail to men at four time
points: baseline/recruitment and at 3, 6, and 9 months
after recruitment and intervention commencement.
Mindfulness skills are included as potential mediators
of intervention effect. Primary outcomes are anxiety,
depression and cancer-specific distress. Secondary
outcomes are global QoL and benefit finding. Disease
variables (e.g. cancer grade, stage, time since diagnosis,
time since treatment) will be assessed through medical
records review.
Mediators
Mindfulness: The Five Facet Mindfulness Questionnaire
(FFMQ) [18] is being used to measure the participants’
engagement with the principles of mindfulness.
Adherence to Practice: Adherence to mindfulness
practice is assessed by participants completing a daily
home practice form.
Primary outcome variables
Anxiety and Depression: The Brief Symptom Inventory-18
[19] is providing a global measure of current psychological
distress with subscale scores for anxiety, depression, and
somatisation.
Cancer-Specific Distress: The Impact of Events Scale
(IES) [20,21] and the PSA Anxiety subscale of the Memorial
Anxiety Scale for Prostate Cancer (MAX-PC) [22] is being
used to measure men’s cancer-specific distress.
Secondary outcome variables
Quality of Life: The Functional Assessment of Cancer
Therapy – Prostate (FACT-P) [23] is being used to assess
the men’s perceived global quality of life across 5 domains:
physical, social/family, emotional, functional well-being,
and prostate cancer-specific concerns.
Benefit Finding: Positive adjustment is being measured
with the Posttraumatic Growth Inventory assessing
perceived positive outcomes resulting from a diagnosis
of cancer [24].
Statistical analyses
The study is a two-condition randomised controlled trial
with repeated measures across time and continuous
outcome variables. The analysis of longitudinal differences
in outcome will be by multilevel (mixed) modelling
(MLM). These procedures allow the testing of typical
group level predictions such as Hypotheses 1 to 3 that
men in the intervention condition will have better
outcomes than the patient education group. However, byincorporating the hierarchical structure of assessment
points nested within individual men they further permit
the true assessment of individual change in psychological
outcomes and of potential mediators of such change
(Hypothesis 4). Consequently (and unlike traditional
approaches), this model deals with the heterogeneity of
responses, such as that expected in the outcomes of the
proposed study, by allowing such variation as random
effects within the model. MLM has the advantage of
allowing use of all available data points, which
maximizes power to detect effects and reduces bias
owing to missing data in longitudinal studies.
Discussion
The study will provide recommendations about effective
psychological interventions to reduce anxiety, depression
and cancer-specific distress in men with advanced prostate
cancer. To our knowledge, to date no psychological inter-
vention studies have targeted men with advanced prostate
cancer specifically; or trialled remotely delivered mindful-
ness interventions in cancer populations [9]. This research
will overcome these limitations. If proven effective, the
intervention will be able to be utilised in a range of settings
including broad reach tele-health support programs; and
through support services and support groups internation-
ally. This means that project outputs will be immediately
translatable into practice to reduce psychological distress
and improve the quality of life of men with advanced
prostate cancer.
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